Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
Morgan and Bristol Myers Squibb that you may have missed from earlier this week. Takeda Pharmaceutical has paid $100 million for an exclusive option to license a blood cancer medicine from China-based Ascentage Pharma . Known as olverembatinib, the medicine is already approved and marketed in China for certain adult patients with chronic myeloid leukemia. It blocks members of the "tyrosine kinase" enzyme family that are integral to the onset and development of CML. — Jacob Bell The Food and Drug Administration has advised vaccine manufacturers to target, if possible, the KP.2 coronavirus strain in updating their COVID-19 shots this year. The recommendation follows an advisory committee meeting earlier this month, during which experts favored an update that broadly covers the JN.1 virus lineage, which includes KP.2. While the FDA initially communicated that preference to companies, it is now pushing KP.2 specifically based on current data. The agency doesn't anticipate this change
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies [Yahoo! Finance]Yahoo! Finance
- Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV TherapiesBusiness Wire
- Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia [Yahoo! Finance]Yahoo! Finance
- Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune ThrombocytopeniaBusiness Wire
- Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 6/17/24 - Form 6-K
- 6/11/24 - Form 6-K
- 6/10/24 - Form 6-K
- TAK's page on the SEC website